|
Active substance |
lenalidomide |
|
Holder |
Celgene sprl |
|
Status |
closed |
|
Indication |
diffuse large B cell lymphoma in patients who already received at least two prior treatment lines |
|
Public documents |
|
|
Last update |
29/06/2022 |
Revlimid
Last updated on 10/09/2024